Your browser doesn't support javascript.
loading
De novo and inherited monoallelic variants in TUBA4A cause ataxia and spasticity.
Benkirane, Mehdi; Bonhomme, Marion; Morsy, Heba; Safgren, Stephanie L; Marelli, Cecilia; Chaussenot, Annabelle; Smedley, Damian; Cipriani, Valentina; de Sainte-Agathe, Jean-Madeleine; Ding, Can; Larrieu, Lise; Vestito, Letizia; Margot, Henri; Lesca, Gaetan; Ramond, Francis; Castrioto, Anna; Baux, David; Verheijen, Jan; Sansa, Emna; Giunti, Paola; Haetty, Aline; Bergougnoux, Anne; Pointaux, Morgane; Ardouin, Olivier; Van Goethem, Charles; Vincent, Marie-Claire; Hadjivassiliou, Marios; Cossée, Mireille; Rouaud, Tiphaine; Bartsch, Oliver; Freeman, William D; Wierenga, Klaas J; Klee, Eric W; Vandrovcova, Jana; Houlden, Henry; Debant, Anne; Koenig, Michel.
Afiliação
  • Benkirane M; Laboratoire de Génétique moléculaire, Institut Universitaire de Recherche Clinique, CHU of Montpellier, 34090 Montpellier, France.
  • Bonhomme M; PhyMedExp Univ Montpellier, CNRS UMR 9214, INSERM U1046, 34090 Montpellier, France.
  • Morsy H; Department of Medical Genetics, Laboratory of Genomics Medicine, Sorbonne University, APHP, 75006 Paris, France.
  • Safgren SL; CRBM (Centre de Recherche en Biologie cellulaire de Montpellier), CNRS, Université de Montpellier, 34293 Montpellier, France.
  • Marelli C; Department of Neuromuscular Diseases, UCL Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK.
  • Chaussenot A; Human Genetics Department, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
  • Smedley D; Department of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Cipriani V; MMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France; Expert center for Neurogenetic Diseases, CHU of Montpellier, 34095 Montpellier, France.
  • de Sainte-Agathe JM; Department of Medical Genetics, CHU of Nice, 06000 Nice, France.
  • Ding C; William Harvey Research Institute, Clinical Pharmacology and Precision Medicine, Queen Mary University of London, London EC1M 6BQ, UK.
  • Larrieu L; William Harvey Research Institute, Clinical Pharmacology and Precision Medicine, Queen Mary University of London, London EC1M 6BQ, UK.
  • Vestito L; UCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
  • Margot H; UCL Genetics Institute, University College London, London WC1E 6BT, UK.
  • Lesca G; Department of Medical Genetics, Laboratory of Genomics Medicine, Sorbonne University, APHP, 75006 Paris, France.
  • Ramond F; Institute of human genetics, University of Medicine Mainz, Mainz 55128, Germany.
  • Castrioto A; Laboratoire de Génétique moléculaire, Institut Universitaire de Recherche Clinique, CHU of Montpellier, 34090 Montpellier, France.
  • Baux D; William Harvey Research Institute, Clinical Pharmacology and Precision Medicine, Queen Mary University of London, London EC1M 6BQ, UK.
  • Verheijen J; Department of Medical Genetics, CHU of Bordeaux, 33404 Bordeaux, France.
  • Sansa E; Department of Medical Genetics, University Hospitals of Lyon, and Université Claude Bernard Lyon1, 69500 Lyon, France.
  • Giunti P; Department of Medical Genetics, CHU of Saint-Etienne, 42055 Saint-Etienne, France.
  • Haetty A; Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology Department, 38706 Grenoble, France.
  • Bergougnoux A; Laboratoire de Génétique moléculaire, Institut Universitaire de Recherche Clinique, CHU of Montpellier, 34090 Montpellier, France.
  • Pointaux M; INM, Institut des Neurosciences Montpellier, INSERM, 34000 Montpellier, France.
  • Ardouin O; Montpellier BioInformatics for Clinical Diagnosis (MOBIDIC), Molecular Medicine and Genomics Platform (PMMG), CHU Montpellier, 34295 Montpellier, France.
  • Van Goethem C; Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Vincent MC; Department of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Institute of Neurology, London WC1N 3BG, UK.
  • Hadjivassiliou M; Department of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Institute of Neurology, London WC1N 3BG, UK.
  • Cossée M; INM, Institut des Neurosciences Montpellier, INSERM, 34000 Montpellier, France.
  • Rouaud T; Laboratoire de Génétique moléculaire, Institut Universitaire de Recherche Clinique, CHU of Montpellier, 34090 Montpellier, France.
  • Bartsch O; PhyMedExp Univ Montpellier, CNRS UMR 9214, INSERM U1046, 34090 Montpellier, France.
  • Freeman WD; Laboratoire de Génétique moléculaire, Institut Universitaire de Recherche Clinique, CHU of Montpellier, 34090 Montpellier, France.
  • Wierenga KJ; Laboratoire de Génétique moléculaire, Institut Universitaire de Recherche Clinique, CHU of Montpellier, 34090 Montpellier, France.
  • Klee EW; Montpellier BioInformatics for Clinical Diagnosis (MOBIDIC), Molecular Medicine and Genomics Platform (PMMG), CHU Montpellier, 34295 Montpellier, France.
  • Vandrovcova J; Montpellier BioInformatics for Clinical Diagnosis (MOBIDIC), Molecular Medicine and Genomics Platform (PMMG), CHU Montpellier, 34295 Montpellier, France.
  • Houlden H; Laboratoire de Génétique moléculaire, Institut Universitaire de Recherche Clinique, CHU of Montpellier, 34090 Montpellier, France.
  • Debant A; Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2HQ, UK.
  • Koenig M; Laboratoire de Génétique moléculaire, Institut Universitaire de Recherche Clinique, CHU of Montpellier, 34090 Montpellier, France.
Brain ; 2024 Jun 17.
Article em En | MEDLINE | ID: mdl-38884572
ABSTRACT
Alpha-tubulin 4A encoding gene (TUBA4A) has been associated with familial amyotrophic lateral sclerosis (fALS) and fronto-temporal dementia (FTD), based on identification of likely pathogenic variants in patients from distinct ALS and FTD cohorts. By screening a multicentric French cohort of 448 unrelated probands presenting with cerebellar ataxia, we identified ultra-rare TUBA4A missense variants, all being absent from public databases and predicted pathogenic by multiple in-silico tools. In addition, gene burden analyses in the 100,000 genomes project (100KGP) showed enrichment of TUBA4A rare variants in the inherited ataxia group compared to controls (OR 57.0847 [10.2- 576.7]; p = 4.02 x10-07). Altogether, we report 12 patients presenting with spasticity and/or cerebellar ataxia and harboring a predicted pathogenic TUBA4A missense mutation, including 5 confirmed de novo cases and a mutation previously reported in a large family presenting with spastic ataxia. Cultured fibroblasts from 3 patients harboring distinct TUBA4A missense showed significant alterations in microtubule organisation and dynamics, providing insight of TUBA4A variants pathogenicity. Our data confirm the identification of a hereditary spastic ataxia disease gene with variable age of onset, expanding the clinical spectrum of TUBA4A associated phenotypes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Brain Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Brain Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França
...